In Brief: Laserscope
This article was originally published in The Gray Sheet
Executive SummaryLaserscope Aura: Firm is gearing up to begin shipments of the surgical and dermatological laser system in October following April 510(k) clearance by FDA. The device, which fills out the firm's exisiting line of lasers with dermatologic applications including the Orion and 800 Series systems, will be targeted at the physician's office and outpatient surgery markets. In the dermatology area, Laserscope says the Aura can be used to treat "vascular lesions such as leg veins, hemangiomas, birth marks and facial spider veins, as well as benign occurrences such as brown sun spots, liver spots, skin tags, warts and moles." The device also can be used for ear, nose and throat applications, Laserscope says. The company plans to sell the system through its 30-person direct sales force in the U.S., U.K, and France, and through distributors in other countries. Aura can be used in combination with Laserscope's SmartScan microprocessor-controlled dermatologic scanning device, introduced last year, and will be priced between $49,000 and $70,000...
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.